Slamon DJ - Search Results

1

Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab.

Mass RD, Press MF, Anderson S, Cobleigh MA, Vogel CL, Dybdal N, Leiberman G, Slamon DJ. Mass RD, et al. Among authors: slamon dj. Clin Breast Cancer. 2005 Aug;6(3):240-6. doi: 10.3816/CBC.2005.n.026. Clin Breast Cancer. 2005. PMID: 16137435

2

HER-2/neu oncogene expression and DNA ploidy analysis in breast cancer.

Bacus SS, Bacus JW, Slamon DJ, Press MF. Bacus SS, et al. Among authors: slamon dj. Arch Pathol Lab Med. 1990 Feb;114(2):164-9. Arch Pathol Lab Med. 1990. PMID: 1967930

3

Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues.

Press MF, Cordon-Cardo C, Slamon DJ. Press MF, et al. Among authors: slamon dj. Oncogene. 1990 Jul;5(7):953-62. Oncogene. 1990. PMID: 1973830

4

HER-2/neu oncogene amplification and expression in breast and ovarian cancers.

Press MF, Jones LA, Godolphin W, Edwards CL, Slamon DJ. Press MF, et al. Among authors: slamon dj. Prog Clin Biol Res. 1990;354A:209-21. Prog Clin Biol Res. 1990. PMID: 1978943 Review. No abstract available.

5

Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis.

Press MF, Pike MC, Hung G, Zhou JY, Ma Y, George J, Dietz-Band J, James W, Slamon DJ, Batsakis JG, et al. Press MF, et al. Among authors: slamon dj. Cancer Res. 1994 Nov 1;54(21):5675-82. Cancer Res. 1994. PMID: 7522962

6

Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression.

Press MF, Hung G, Godolphin W, Slamon DJ. Press MF, et al. Among authors: slamon dj. Cancer Res. 1994 May 15;54(10):2771-7. Cancer Res. 1994. PMID: 7909495

7

Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization.

Pauletti G, Godolphin W, Press MF, Slamon DJ. Pauletti G, et al. Among authors: slamon dj. Oncogene. 1996 Jul 4;13(1):63-72. Oncogene. 1996. PMID: 8700555

8

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.

Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y, Hung G, Robinson RA, Harris C, El-Naggar A, Slamon DJ, Phillips RN, Ross JS, Wolman SR, Flom KJ. Press MF, et al. Among authors: slamon dj. J Clin Oncol. 1997 Aug;15(8):2894-904. doi: 10.1200/JCO.1997.15.8.2894. J Clin Oncol. 1997. PMID: 9256133

9

HER-2/neu as a predictive marker of response to breast cancer therapy.

Pegram MD, Pauletti G, Slamon DJ. Pegram MD, et al. Among authors: slamon dj. Breast Cancer Res Treat. 1998;52(1-3):65-77. doi: 10.1023/a:1006111117877. Breast Cancer Res Treat. 1998. PMID: 10066073 Review.

10

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.

Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ. Cobleigh MA, et al. Among authors: slamon dj. J Clin Oncol. 1999 Sep;17(9):2639-48. doi: 10.1200/JCO.1999.17.9.2639. J Clin Oncol. 1999. PMID: 10561337 Corrected and republished. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

320 results

Search Page